StemCells, Inc.   Report issue

For profit Phase 1 Phase 2
Founded: Newark CA United States (1988)
Status: Defunct (2016)

Organization Overview

First Clinical Trial
2006
NCT00337636
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (1)

human central nervous system stem cells (8 trials)

Drugs in Phase 1 Trials (1)

cns stem cells (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Aneurysm, Dissecting (Phase 2)

Geographic Atrophy (Phase 2)

Macular Degeneration (Phase 2)

Neuronal Ceroid-Lipofuscinoses (Phase 1)

Pelizaeus-Merzbacher Disease (Phase 1)

Spinal Cord Injuries (Phase 2)

Spinal Injuries (Phase 2)

Thoracic Injuries (Phase 2)

Wounds and Injuries (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 9
  • # of Trial APIs: 2